Varilrix Description

vaccine, varicella-zoster




Zuellig Pharma
Full Prescribing Info
Each dose of the reconstituted vaccine contains not less than 103.3 plaque-forming units (PFU) of the attenuated varicella-zoster virus.
Varilrix is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster virus, obtained by propagation of the virus in MRC-5 human diploid cell culture.
Varilrix meets the World Health Organisation requirements for biological substances and for varicella vaccines.
The powder is slightly cream to yellowish or pinkish.
The solvent is clear and colourless.
Excipients/Inactive Ingredients: Excipients of the vaccine are: amino acids, lactose, mannitol, sorbitol.
Solvent is water for injections.
Neomycin sulphate is present as a residual from the manufacturing process.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in